AlphAIAlphAI — Financial news for AI agents
investing.comOCT 61 min read$CGEN

Stifel reiterates Compugen stock rating on ovarian trial update

Stifel reiterated a Buy rating and $4.00 price target on Compugen (CGEN) after its investor event, citing a 73% upside potential. The event focused on the MAIA-ovarian trial and expanded UnigenX platform. Compugen reported Q2 revenue of $2.6M, a net loss of $7.0M, and a strong cash position. H.C. Wainwright also maintained a Buy rating with a $4.00 target.

Original reporting
investing.com
Published Oct 6, 2026, 12:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 12:45 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$CGEN
Neutral
medium confidence
Mentioned
$CGEN
Relevance
4/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$CGENNeutralLow
01

Why it matters

The analyst's reiteration reinforces existing price expectations but does not introduce fresh material that would shift the stock significantly.

02

Market read

Limited relevance; primarily of interest to niche biotech investors.

03

What to watch

Potential competitive landscape in ovarian cancer therapies and the need for actual trial results to validate the upside.

Relevance 4/10Novelty 2/10Timing: none

Background

Compugen (NASDAQ:CGEN) is a small‑cap biotech focused on cancer immunotherapy. The article repeats an analyst's rating and target after a virtual event that provided trial progress details but no new data.

Company-level read

Ticker impact

$CGENNeutralMedium confidence
Context

Stifel reiterated a Buy rating and $4.00 price target for Compugen after its virtual investor event discussing the MAIA-ovarian trial update.

Expected impact

likely modest buying pressure as the market prices in the reiterated target.

Evidence & confidence

The rating and target are not new information; they restate existing expectations, offering limited actionable insight.

Market effects

Sector

Minimal impact on the broader biotech sector; trial update is a routine progress report.

Regional

No discernible regional effect.

Global

Limited to investors tracking early‑stage oncology biotech.

Counterpoint

What could challenge this read

The reiteration may be overly optimistic given the trial is still early and no efficacy data released.

Key entities

  • Company
    Compugen Ltd.

    Biotech firm developing ovarian cancer therapy.

  • Analyst
    Stifel

    Equity research firm issuing the Buy rating.

Read at source← All news

Related articles

AUG 3
$CGENMed

Compugen Reports Second Quarter 2026 Results

Compugen Ltd. (NASDAQ: CGEN) reported Q2 2026 results and a corporate update. The MAIA-ovarian trial of COM701 is progressing, with median progression-free survival interim data expected in Q1 2027. Partner AstraZeneca presented GEMINI-Hepatobiliary overall survival data for rilvegostomig (median 16.8 months). Cash was about $125.3M, funding operations into 2029. Q2 revenue was ~$2.6M vs ~$1.3M in 2025; net loss ~$7.0M.

prnewswire.com7 min
OCT 8
$RCLHigh

Jefferies upgrades Royal Caribbean stock rating on improved revenue outlook

Jefferies upgraded Royal Caribbean (RCL) to Buy with a $330 price target, citing improved occupancy and revenue per passenger. RCL trades at $282.32, with a P/E ratio of 17.66. Jefferies raised revenue estimates for Q3 2026 and FY 2027, projecting net yield growth and higher EBITDA. Despite lower EPS estimates, the firm increased valuation multiples. Other analysts also upgraded RCL, citing strategic developments and positive yield outlooks.

investing.com2 min
OCT 8
$NGNEHigh

JPMorgan initiates Neurogene stock rating at Overweight on gene therapy potential

JPMorgan initiated coverage on Neurogene Inc. (NASDAQ: NGNE) with an Overweight rating and a $60.00 price target, citing potential in its gene therapy NGN-401 for Rett syndrome. The stock trades at $25.87, with analysts maintaining a Strong Buy consensus. Neurogene expects key data readouts in 2H27, with a market cap of $518 million and high volatility. Recent analyst adjustments include lowered price targets from H.C. Wainwright and Canaccord, both maintaining Buy ratings.

investing.com2 min
OCT 8
$BHVNMed

Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' Disease

Biohaven (BHVN) has entered a licensing agreement with Ono Pharma for its extracellular IgG degraders in Japan and select Asian regions. Biohaven will receive up to $100 million in payments, including $80 million upfront, and 20% royalties on net sales. The lead candidate, BHV-1300, is in Phase 3 trials for Graves' disease. Biohaven retains rights to the portfolio outside the licensed territory.

prnewswire.com2 min